The Latest in Multiple Myeloma

Daratumumab Quadruplet Supported Transplant-Ineligible MM

October 3, 2024

Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes

September 30, 2024

Does Medicare Advantage Offer Higher-Value Chemotherapy?

September 26, 2024

AACR Cancer Progress Report: Big Strides and Big Gaps

September 26, 2024

Isatuximab Approved First-Line for Transplant-Ineligible MM

September 23, 2024

Multiple Myeloma

Cancer Risk: Are Pesticides the New Smoking?

September 20, 2024

Debate: Should CAR T Best Be Used in Early MM Relapse?

September 12, 2024

A Simple Blood Test May Predict Cancer Risk in T2D

September 11, 2024

Do Clonal Hematopoiesis and Mosaic Chromosomal Alterations Increase Solid Tumor Risk?

September 6, 2024

Teclistamab Promising as a Treatment of Last Resort for Refractory Autoimmune Diseases

September 5, 2024

Multiple Myeloma

Cancer Treatment 101: A Primer for Non-Oncologists

August 23, 2024

Multiple Myeloma: New Treatments Aid Patient Subgroups

August 22, 2024

Multiple Myeloma

When Childhood Cancer Survivors Face Sexual Challenges

August 22, 2024

FDA Issues Complete Response Letter for Myeloma Drug

August 21, 2024

Multiple Myeloma

FDA Approves Axatilimab for Chronic GVHD

August 15, 2024